<DOC>
	<DOCNO>NCT00648726</DOCNO>
	<brief_summary>To validate efficacy safety azithromycin treatment Chinese patient hospitalize community-acquired pneumonia ( CAP ) , compare cefuroxime combination cefuroxime plus oral erythromycin .</brief_summary>
	<brief_title>An Open , Prospective , Randomized , Multicenter Study Efficacy Safety Intravenous Followed Oral Azithromycin Versus Cefuroxime Alone With Oral Erythromycin Treatment Chinese Patients Who Were Hospitalized Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<mesh_term>Cefuroxime axetil</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Patients hospitalized diagnosis community acquire pneumonia ( CAP ) define presence new infiltrate ( ) include manifestation consolidation , patchy , diffuse interstitial inflammation chest Xray without pleural effusion plus least 1 follow : new cough expectoration progression respiratory symptom purulent sputum without chest pain ; fever ; auscultatory finding rale evidence pulmonary consolidation ; blood leukocyte count &gt; 10×109/L &lt; 4×109/L without &gt; 15 % band blood leukocyte count 4 10 neutropils great equal 75 % Patients hospital acquire pneumonia , aspiration pneumonia , severe pneumonia , history postobstructive pneumonia , active tuberculosis bronchitis , bronchiectasis chronic obstructive pulmonary disease without evidence acute infection eligible study Patients treat systemic antibiotic within 72 hour prior study entry eligible unless medication , opinion investigator , classify fail</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>